Health Catalyst, Inc. (NASDAQ:HCAT) Director Timothy G. Ferris sold 5,867 shares of the business’s stock in a transaction dated Monday, January 11th. The shares were sold at an average price of $45.04, for a total value of $264,249.68. Following the completion of the transaction, the director now owns 11,310 shares in the company, valued at $509,402.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
HCAT opened at $47.32 on Thursday. The stock has a market cap of $2.01 billion, a price-to-earnings ratio of -21.03 and a beta of 0.54. The stock’s 50 day moving average price is $40.85 and its 200-day moving average price is $35.81. Health Catalyst, Inc. has a one year low of $17.48 and a one year high of $47.54. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.90 and a current ratio of 4.90.
Health Catalyst (NASDAQ:HCAT) last released its earnings results on Sunday, November 15th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.06. The firm had revenue of $47.20 million for the quarter, compared to analysts’ expectations of $44.59 million. Health Catalyst had a negative return on equity of 25.57% and a negative net margin of 48.17%. The company’s quarterly revenue was up 19.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.27) earnings per share. As a group, analysts predict that Health Catalyst, Inc. will post -1.56 earnings per share for the current fiscal year.
Several brokerages have recently commented on HCAT. Cantor Fitzgerald restated an “overweight” rating on shares of Health Catalyst in a research report on Wednesday, November 11th. BidaskClub upgraded Health Catalyst from a “buy” rating to a “strong-buy” rating in a research report on Friday, December 25th. ValuEngine downgraded Health Catalyst from a “buy” rating to a “hold” rating in a research report on Thursday, December 17th. Smith Barney Citigroup boosted their target price on Health Catalyst from $40.00 to $49.00 in a research report on Tuesday, December 15th. Finally, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell boosted their target price on Health Catalyst from $40.00 to $49.00 in a research report on Tuesday, December 15th. Two investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $42.07.
About Health Catalyst
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its solutions include a cloud-based data platform, analytics software, and professional services. The company was founded in 2008 and is headquartered in Salt Lake City, Utah.
Read More: What is the NASDAQ Stock Market?
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.